Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Phase 2 crawled time : 12:15 save search
Alkermes Announces First Subject Dosed in Phase 1 Study of ALKS 1140 for the Treatment of Neurodegenerative and Neurological Disorders
Published: 2021-11-11 (Crawled : 12:15) - prnewswire.com
ALKS | $24.65 1.61% 1.62% 1.7M
|
Health Technology
|
| O: -1.59%
H: 1.86%
C: -1.05%
treatment neurodegenerative neurological phase 1 phase 2
Tonix Pharmaceuticals Presents Phase 1 Formulation Development Data for TNX-601 CR in a Poster Presentation at CNS Summit 2021
Published: 2021-11-09 (Crawled : 12:15) - globenewswire.com
TNXP | $0.16 2.04% 1.2% 940K
|
Health Technology
|
| O: 2.43%
H: 0.0%
C: 0.0%
presentation phase 1 phase 2
Phase 2 Clinical Trial Data of NurOwn® in Progressive MS Will Be Presented at the 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS)
Published: 2021-10-14 (Crawled : 12:15) - biospace.com/
BCLI A | $0.545 3.81% 1.67% 190K
|
Health Technology
|
| O: 3.17%
H: 0.0%
C: -3.38%
multiple sclerosis treatment phase 2 europe sclerosis research trial
VistaGen Therapeutics Expands Clinical Development of PH94B with Initiation of Phase 2A Trial in Adjustment Disorder
Published: 2021-10-14 (Crawled : 12:15) - globenewswire.com
VTGN | $4.72 -2.28% -1.68% 150K
|
Health Technology
|
| O: 0.8%
H: 1.59%
C: -0.4%
phase 2 trial phase 2b ph94
Hill International to Provide Construction Management Services for the PA Turnpike/I-95 Interchange, Phase 2 Project
Published: 2021-10-06 (Crawled : 12:15) - globenewswire.com
HIL | $3.39 0.3%
|
Industrial Services
|
| O: 0.47%
H: 0.0%
C: -0.94%
phase 2
Arrowhead Earns $10 Million Phase 1 Milestone Payment
Published: 2021-09-28 (Crawled : 12:15) - biospace.com/
JNJ | News | $148.53 -0.69% 0.18% 7.5M
|
Health Technology
|
| O: -0.04%
H: 0.5%
C: -0.18%
ARWR | $23.29 -2.06% -2.13% 810K
|
Health Technology
|
| O: -0.99%
H: 0.0%
C: -6.56%
phase 1 phase 2 phase 3 milestone
Edesa Biotech Announces Positive Phase 2 Data of Its Monoclonal Antibody in Hospitalized COVID-19 Patients
Published: 2021-09-20 (Crawled : 12:15) - biospace.com/
EDSA | $4.31 -3.47% -3.84% 5.1K
|
Health Technology
|
| O: 68.6%
H: 26.98%
C: 26.14%
covid phase 2 positive antibody biotech iot covid-19
Oramed's Phase 2 Oral Insulin NASH Trial Reaches Over 50% Enrollment
Published: 2021-09-15 (Crawled : 12:15) - prnewswire.com
ORMP A | $2.37 0.85% 1.05% 41K
|
Health Technology
|
| O: -1.26%
H: 5.89%
C: 3.24%
phase 2 insulin nash trial enroll
RedHill Biopharma Reports Top-Line Data from Opaganib Phase 2/3 Study in Severe COVID-19 Patients
Published: 2021-09-14 (Crawled : 12:15) - prnewswire.com
RDHL | $0.4199 -1.85% -3.08% 190K
|
Health Technology
|
| O: -32.93%
H: 7.07%
C: 0.4%
covid phase 2 biopharma phase 2/3 opaganib topline
Medicenna Doses First Patient in MDNA11 Phase 1/2 ABILITY Study
Published: 2021-09-14 (Crawled : 12:15) - globenewswire.com
MDNA | $0.157 -0.32% 1.3M
|
Health Technology
|
| O: 1.91%
H: 1.13%
C: -3.75%
phase 1 phase 3 phase 2
Perception Neuroscience initiates Phase 2a study of PCN-101 (R-ketamine) for treatment resistant depression
Published: 2021-09-14 (Crawled : 12:15) - globenewswire.com
ATAI | $1.87 -5.08% -5.07% 840K
|
Manufacturing
|
| O: -1.28%
H: 3.31%
C: 1.17%
treatment phase 2 depression phase 2b ketamine
Galecto Announces First Patient Treated in Phase 2 Trial of Oral Galectin-3 Inhibitor GB1211 in Liver Cirrhosis
Published: 2021-09-13 (Crawled : 12:15) - globenewswire.com
GLTO | $0.671 -4.23% -7.77% 76K
|
Health Technology
|
| O: 0.0%
H: 2.27%
C: -2.27%
phase 2 cirrhosis liver trial gb1211 galectin-3 ykl-40
Metacrine Achieves Full Enrollment for MET642 Phase 2a Trial in Patients With Nash
Published: 2021-09-09 (Crawled : 12:15) - globenewswire.com
MTCR | $0.5814 -5.14% 84K
|
Health Technology
|
| O: 1.01%
H: 4.0%
C: 0.0%
phase 2 nash trial met642 phase 2b enroll
Brickell Biotech Acquires Exclusive Rights to Phase 1-Ready DYRK1A Inhibitor Program and Novel Platform Targeting Autoimmune and Inflammatory Diseases
Published: 2021-09-01 (Crawled : 12:15) - biospace.com/
BBI | $2.12 16.04%
|
Health Technology
|
| O: 0.2%
H: 1.35%
C: 1.22%
disease phase 1 biotech iot phase 2 phase 3
White Metal JV Partner Leocor Gold Plans Phase 1 Work Program on the Startrek Gold Property, Central Newfoundland
Published: 2021-09-01 (Crawled : 12:15) - globenewswire.com
NFGC | News | $3.66 -3.68% 0.0% 470K
|
| Email alert
Add to watchlist
phase 2 phase 3 phase 1 leo
Ayala Pharmaceuticals to Present Clinical Data from Ongoing Phase 2 ACCURACY Trial and New Preclinical Results from Combination Study of AL101 at the European Society for Medical Oncology (ESMO) Virtual Congress 2021
Published: 2021-09-01 (Crawled : 12:15) - globenewswire.com
BMY | $48.86 -0.27% 0.98% 14M
|
Health Technology
|
| O: 0.64%
H: 0.0%
C: -2.2%
AYLA | $0.5036 5.84% -0.7% 0
|
Health Technology
|
| O: -2.6%
H: 6.97%
C: 6.81%
phase 2 europe ongoing results trial preclinical pre-clinical
Data from NIH/NHLBI-Sponsored Phase 2 Trial of Fostamatinib in Hospitalized COVID-19 Patients Published in Clinical Infectious Diseases
Published: 2021-09-01 (Crawled : 12:15) - biospace.com/
LLY | News | $732.2 -1.81% -0.84% 1.7M
|
Health Technology
|
| O: 0.1%
H: 0.09%
C: -0.44%
RIGL | $1.125 -1.32% -1.33% 6.5M
|
Health Technology
|
| O: -0.26%
H: 8.84%
C: 8.44%
covid disease phase 2 infectious disease trial
NRx Pharmaceuticals Announces New Finding from ZYESAMI™ (aviptadil) Phase 2b/3 Clinical Trial Demonstrating Clinically Significant Relief from Respiratory Distress in Critical COVID-19
Published: 2021-08-30 (Crawled : 12:15) - prnewswire.com
NRXP 5 d | $3.12 2.3% 1.93% 98K
|
Manufacturing
|
| O: 11.53%
H: 11.56%
C: -0.07%
covid phase 2 respiratory phase 2b trial aviptadil
Galecto Announces First Patient Treated in Phase 2a Trial of the Oral LOXL2 Inhibitor GB2064 in Myelofibrosis (the MYLOX-1 Trial)
Published: 2021-08-18 (Crawled : 12:15) - globenewswire.com
GLTO | $0.671 -4.23% -7.77% 76K
|
Health Technology
|
| O: 4.13%
H: 1.24%
C: -3.47%
phase 2 fibrosis trial phase 2b
Aemetis Receives Final Permit to Build Next 21 Miles of Phase 2 Biogas Pipeline
Published: 2021-08-06 (Crawled : 12:15) - globenewswire.com
AMTX | $3.92 0.51% 0.0% 1M
|
Process Industries
|
| O: 2.58%
H: 9.6%
C: 5.94%
phase 2
Gainers vs Losers
| 61% | 39% |
Top 10 Gainers
CSSE 4 | $0.4253 179.25% 64.77% 210M
|
Consumer Services
BOF | $2.08 77.78% 41.21% 110M
|
ILAG | $0.54 12.27% 40.62% 3.7M
|
LICN | $0.999 78.39% 40.49% 15M
|
AMST | $3.4 70.0% 39.58% 70M
|
Technology Services
MTC | $3.6 60.71% 38.04% 9.1M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.458 14.5% 30.92% 91K
|
Health Services
WHLM | $6.25 35.87% 28.46% 700K
|
Commercial Services
MULN | News | $3.77 38.1% 27.78% 13M
|
Information
Your saved searches
Save your searches and get alerts when important news are released.